Welcome to Scribd. Sign in or start your free trial to enjoy unlimited e-books, audiobooks & documents.Find out more
Download
Standard view
Full view
of .
Look up keyword
Like this
1Activity
0 of .
Results for:
No results containing your search query
P. 1
imovane

imovane

Ratings: (0)|Views: 85|Likes:

More info:

Published by: Canadian_Veterans_Ad on Dec 22, 2011
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

02/05/2013

pdf

text

original

 
 
PRODUCT MONOGRAPHIMOVANE
 ® 
 (zopiclone)Tablets, 5.0 mg and 7.5 mg
Hypnotic and Sedative
 
sanofi-aventis Canada Inc.2150 St. Elzear Blvd. WestLaval, Quebec H7L 4A8Date of Revision:October 30, 2008Submission Control No.: 123999
s-a Version 4.0 dated October 30, 2008
 
 
 
2
NAME OF DRUG
 
IMOVANE
 ® 
 (zopiclone)Tablets, 5.0 mg and 7.5 mgHypnotic and Sedative
ACTIONS, CLINICAL PHARMACOLOGY
IMOVANE (zopiclone), a cyclopyrrolone derivative, is a short-acting hypnotic agent.IMOVANE belongs to a novel chemical class, which is structurally unrelated to existinghypnotics. However, the pharmacological profile of IMOVANE is similar to that of thebenzodiazepines.IMOVANE pharmacological properties are: hypnotic, sedative, anxiolytic, anti-convulsant,muscle-relaxant. These effects are related to a specific agonist action at central receptorsbelonging to the GABAa macromolecular complex, modulating the opening of thechloride ion channel.In sleep laboratory studies of one to 21-day duration in man, zopiclone reduced sleeplatency, increased the duration of sleep and decreased the number of nocturnalawakenings. Zopiclone delayed the onset of REM sleep but did not reduce consistentlythe total duration of REM periods. The duration of stage 1 sleep was shortened, and thetime spent in stage 2 sleep increased. In most studies, stage 3 and 4 sleep tended to beincreased, but no change and actual decreases have also been observed. The effect ofzopiclone on stage 3 and 4 sleep differs from that of the benzodiazepines, whichsuppress slow wave sleep. The clinical significance of this finding is not known.With hypnotic drugs, the duration of hypnotic effect and the profile of unwanted effectsmay be influenced by the alpha (distribution) (t½
α
) and beta (elimination) (t½
β
) half-livesof the administered drug and any active metabolites formed. When half-lives are long, thedrug or metabolite may accumulate during periods of nightly administration and beassociated with impairments of cognitive and motor performance during waking hours. Ifhalf-lives are short, the drug and metabolites will be cleared before the next dose isingested, and carry-over effects related to sedation or CNS depression should be minimalor absent. If the drug has a very short elimination half-life, it is possible that a relativedeficiency (i.e., in relation to the receptor site) may occur at some point in the intervalbetween each night’s use. This sequence of events may account for two clinical findingsreported to occur after several weeks of nightly use of rapidly eliminated benzodiazepinesor benzodiazepine-like hypnotics: 1) increased wakefulness during the last third of thenight and 2) the appearance of increased day-time anxiety (see WARNINGS).
 
 
3
During nightly use and for an extended period, pharmacodynamic tolerance or adaptationto some effects of benzodiazepines or benzodiazepine-like hypnotics may develop.However in two sleep laboratory studies involving 17 patients, there was an absence oftolerance with zopiclone for treatment periods of more than 4 weeks.Rebound insomnia:Some manifestations of rebound insomnia have been reported both in sleep laboratoryand clinical studies following the withdrawal of zopiclone (see PRECAUTIONS).Zopiclone treatment was associated with dose-related residual effects (seePRECAUTIONS).
Pharmacokinetics
 Absorption:Zopiclone is rapidly and well absorbed. Bioavailability is more than 75%, indicating theabsence of a significant first-pass effect. After the administration of 3.75 and 7.5 mgdoses, peak plasma concentrations of 30 and 60 ng/mL, respectively were reached inless than 2 hours. Absorption was similar in males and females.Repeated daily administration of a 7.5 mg oral dose for 14 days did not change thepharmacokinetic characteristics of zopiclone and did not lead to accumulation.Distribution:Zopiclone is rapidly distributed from the vascular compartment (distribution half-life [t½
α
]:1.2 hours) while the elimination half-life is approximately 5 hours (range: 3.8 to 6.5hours). Plasma protein binding is low (approximately 45% in the 25-100 ng/mLconcentration range) and non saturable. The risk of drug interaction arising fromdisplacement of bound drug is low. The distribution volume is 91.8-104.6 liters.Metabolism:Zopiclone is extensively metabolized by three major pathways; only about 4 to 5% of thedrug is excreted unchanged in the urine.An
in vitro 
study indicates that cytochrome P450 (CYP) 3A4 is the major isoenzymeinvolved in the metabolism of zopiclone to both metabolites, and that CYP2C8 is alsoinvolved with N-desmethyl zopiclone formation.
 
The principal metabolites are the N-oxide derivative (~12%), which has weakpharmacological activity in animals, and the N-desmethyl metabolite (~16%), which ispharmacologically inactive.

You're Reading a Free Preview

Download
scribd
/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->